Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Denali Therapeutics (DNLI)
NASDAQ:DNLI
RESEARCH TOOLSreports
Holding DNLI?
Track your performance easily
DNLI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.56 - $33.33
Previous CloseN/A
Volume399.31K
Average Volume (3M)995.83K
Market Cap
$3.12B
Enterprise Value$4.15B
Total Cash (Recent Filing)$178.33M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.58
Next Earnings
Mar 03, 2025EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.76
Shares Outstanding143,921,630
10 Day Avg. Volume1,215,751
30 Day Avg. Volume995,827
Standard Deviation0.18
R-Squared0.17
Alpha0.00209
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.44
Price to Cash Flow (P/CF)-13.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.33
Enterprise Value/Revenue14.12
Enterprise Value/Gross Profit12.56
Enterprise Value/Ebitda-20.56
Forecast
1Y Price Target
$40.83Price Target Upside86.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Denali Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial StabilityDenali guides to a runway into 2028 based on ~$1.3B in cash/equivalent as of 3Q24, providing financial stability for future developments.
Innovation LeadershipDenali Therapeutics is seen as an innovation leader in the brain-shuttle modality, which is gaining recognition for its fair value.
Regulatory SuccessDNL310 receiving FDA Breakthrough Therapy Designation indicates strong potential for the treatment's success.
Bears Say
Clinical Trial ResultsThe trial failed to meet the primary endpoint ALSFRSR and survival through week 24, along with the key secondary endpoints such as muscle strength and respiratory function.
Competitive PressureRARE is a competitor with a pivotal study ongoing for AAV gene therapy for Sanfilippo.
Regulatory ChallengesChanges in the regulatory environment in ALS suggest a 6-month endpoint could not be enough for registration, delaying launch assumptions.
---
Ownership Overview
9.16% Insiders
33.52% Mutual Funds
0.01% Other Institutional Investors
42.49% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DNLI FAQ
What was Denali Therapeutics’s price range in the past 12 months?
Denali Therapeutics lowest stock price was $14.56 and its highest was $33.33 in the past 12 months.
What is Denali Therapeutics’s market cap?
Denali Therapeutics’s market cap is $3.12B.
When is Denali Therapeutics’s upcoming earnings report date?
Denali Therapeutics’s upcoming earnings report date is Mar 03, 2025 which is in 41 days.
How were Denali Therapeutics’s earnings last quarter?
Denali Therapeutics released its earnings results on Nov 06, 2024. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.595 by -$0.035.
Is Denali Therapeutics overvalued?
According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued.
Does Denali Therapeutics pay dividends?
Denali Therapeutics does not currently pay dividends.
What is Denali Therapeutics’s EPS estimate?
Denali Therapeutics’s EPS estimate is -0.82.
How many shares outstanding does Denali Therapeutics have?
Denali Therapeutics has 143,921,630 shares outstanding.
What happened to Denali Therapeutics’s price movement after its last earnings report?
Denali Therapeutics reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.595. Following the earnings report the stock price went up 0.169%.
Which hedge fund is a major shareholder of Denali Therapeutics?
Among the largest hedge funds holding Denali Therapeutics’s share is Baker Bros Advisors LP. It holds Denali Therapeutics’s shares valued at 109M.
---
Denali Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.83 (86.18% Upside)
$40.83 (86.18% Upside)
Blogger Sentiment
Bullish
DNLI Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 24.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 7.1%
Last 30 Days ▲ 7.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
28.09%
12-Months-Change
Fundamentals
Return on Equity
-35.09%
Trailing 12-Months
Asset Growth
17.56%
Trailing 12-Months
Company Description
Denali Therapeutics
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
---
DNLI Stock 12 Month Forecast
Average Price Target
$40.83
▲(86.18% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Bluebird Bio
―
Immatics
―
Fate Therapeutics
―
Crispr Therapeutics AG
―
Voyager Therapeutics
―
Best Analysts Covering DNLI
1 Year
1 Year Success Rate
5/10 ratings generated profit
1 Year Average Return
+38.60%
reiterated a buy rating 5 months ago
Copying Salveen Richter's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +38.60% per trade.
---